CompsDesk · Peer benchmark preview

Agios Pharmaceuticals, Inc. vs its sector — the six numbers your board asks for.

Computed from AGIO's own SEC filings (FY2025), benchmarked against ABCL and ADCT. Every figure is deterministic — no estimates, no AI math — and cites the exact filing in the full pack.

6 CORE METRICS · GUARANTEED
Metric AGIO ABCL ADCT Peer med. Pctile
Revenue $54.0M $75.1M $81.4M $78.2M 0th
Revenue growth (YoY) 48.0% 160.6% 14.9% 87.7% 50th
Operating margin -873.9% -289.0% -149.3% -219.2% 0th
Net margin -764.0% -194.9% -175.3% -185.1% 0th
FCF margin -698.3% -231.7% -173.8% -202.8% 0th
Capex % of revenue 8.0% 56.9% 0.3% 28.6% 50th
Gross margin
SG&A % · R&D % · tax rate
Net debt/EBITDA · cash-conversion cycle · buybacks
+ up to 8 extended metrics, trends for every filed year & up to 12 peers in your full board-ready pack — PDF + CSV, every number cited to its filing.
Get AGIO's full pack — $249 → Add your own peers first
↗ Copy link ✉ Forward to your CFO / board

Green/red = better/worse than the peer median where direction is unambiguous. Percentile = share of these peers at or below AGIO's value. The full pack adds up to 12 same-sector peers you choose, up to 8 extended metrics where disclosed, trends for every filed year (up to five), and a provenance table citing every figure to its 10-K. Delivered within one business day; 14-day refund if any figure misstates its cited filing. Informational benchmarking from public SEC data — not investment advice. — Sam, CompsDesk